LONDON (ShareCast) - LED technology provider Dialight was one of today’s fallers after it said results were hit by the weak dollar.
Pre-tax profit was flat at £1.3m, in line with market expectations, while sales was down 4% to £28.9m.
"With most of Dialight's sales and profits generated in US Dollars, the recent exchange movements have impacted the company's first half result markedly," said the group.
Vernalis shares were higher after the US Food and Drug Administration said it is targeting 30 September as the date for issuing an action letter for the supplemental New Drug Application for Frova 2.5 mg tablets.
Vernalis and its partner Endo Pharmaceuticals added that they intend to continue with their existing commercial plan, which includes the commercial launch of the anti-migraine drug in January 2008.
1.50p ()
